Induction of Differentiation of B-Cell Leukemia Cell Lines JVM-2 and EHEB bj Bryostatin 1
作者:
BoZhen,
GignacSuzanne M.,
UphoffCord C.,
QuentmeierHilmar,
SteubeKlaus G.,
DrexlerHans G.,
期刊:
Leukemia&Lymphoma
(Taylor Available online 1993)
卷期:
Volume 10,
issue 1-2
页码: 135-142
ISSN:1042-8194
年代: 1993
DOI:10.3109/10428199309147367
出版商: Taylor&Francis
关键词: B-cell differentiation;leukemia cells lines;Bryostatin 1
数据来源: Taylor
摘要:
The effects of bryostatin 1 (Bryo 1), a protein kinase C (PKC) activator, on proliferation, differentiation and macromolecular synthesis were investigated in the two cell lines EHEB and JVM-2, established from patients with chronic B-cell leukemia. Treatment with Bryo 1 inhibited the proliferation, DNA and RNA synthesis in a time- and dose-dependent fashion. The cells differentiated along the B-cell pathway to plasmacytoid cells as judged by morphological examination and increased their production and secretion of immunoglobulins. c-myc mRNA expression was induced in both cell lines. The phorbol ester TPA, a pharmacological PKC activator, had similar differentiation-inducing effects. The bio-modulators failed to induce significant alterations in the cell surface marker profile. Except for their surface markers, all parameters studied were more strongly altered in JVM-2 than in EHEB cells. JVM-2 was established from a patient with B-prolymphocytic leukemia (PLL), whereas EHEB originated from a case of B-chronic lymphocytic leukemia (CLL). These data support the notion that PLL cells appear to be activated B-cells, in contrast to the rather quiescent CLL cells. Since Bryo 1 lacks tumor-promoting activity, this naturally occurring compound, extracted from marine animals, has a potential role in the therapy of B-cell neoplasms as a differentiating agent.
点击下载:
PDF (771KB)
返 回